NewAmsterdam Pharma Company N.V. Ordinary Shares(NAMS)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

NAMS $22.53 —
Snapshot
$22.53
52-Week Range
$21.02 – $42.20
YTD
-36.01%
IV Rank (30D)
44.84
Straddle Price
$3.00
P/C Vol Ratio
0.02
Market Cap
$2.7B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY1.26
Cost of Equity (CAPM)11.87% (VRP-adj)
WACC11.81%
Volatility Risk Premium+37.3pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-41.1%
Book / Price23.0%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-2018.3%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$26.55 (Market Anchor value)
SMA 20 / Bollinger Mid$23.67
Bollinger Width / SMA20124.7% (drives anchor stability)
Net Debt$-0.4B
Market Cap$3B
Peers used for multiples: ACAD, ALKS, CELC, CGON, CRNX, FOLD, KYMR, MIRM
Model Conviction
97%
20-Day Fair Value
≈ by Oct 26, 2026
$23.93
α +5.9% rank 79%
40-Day Fair Value
≈ by Nov 24, 2026
$28.37
α +25.5% rank 75%
60-Day Fair Value
≈ by Dec 23, 2026
$28.53
α +26.2% rank 76%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0% median 43.0× · 3 peers
Peer P/B $33.19 16% median 6.3× · 6 peers
Peer P/S $0.55 16% median 9.4× · 7 peers
Market Anchor (SMA50) $26.55 69% stability 85% (BB-width)
Options Expected (B-L 30d) $22.69 0% 9 strikes · skew -0.25
As of 2026-09-25 · updated
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$2.7B

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan +14.53% 4
Feb +5.76% 4
Mar +0.07% 4
Apr +0.21% 4
May -1.43% 4
Jun -4.56% 4
Jul -3.06% 4
Aug -5.62% 4
Sep -1.66% 4
Oct +7.15% 3
Nov +3.89% 4
Dec +13.95% 4
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $23.45
SMA 50: $26.38
SMA 200: $31.46
Current: $22.57
EMA 12: $22.90
EMA 26: $24.14
MACD: -1.2402 | Signal: 0.1802
BEARISH
ADX (14): 42.55
STRONG TREND
+DI: 11.79
−DI: 21.64

Momentum Oscillators

RSI (14): 38.92
NEUTRAL
Stoch %K: 31.79
Stoch %D: 34.67
Williams %R: -70.02

Volume & Volatility

BB Upper: $26.66
BB Lower: $20.25
NEUTRAL
OBV: 29,472,504
Vol SMA 20: 1,778,894
Vol ROC: -60.03%
ATR: $1.34
True Range: $0.61
HV 20: 58.8%
HV 30: 52.7%
HV 60: 52.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-26T00:00:00 – 2026-09-24T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (confidence level 6/10)

Key Drivers and Primary Risks:

  • Bullish momentum from recent earnings beat
  • Bearish technical signals from MACD and Stochastic indicators
  • High volatility and implied volatility premium

Investment Thesis: NAMS presents a mixed bag, with short-term bearish signals contrasting medium-term bullish trends. The company's recent earnings beat has boosted investor sentiment, but the options market suggests a higher probability of a downside move in the near term.

Recent News Sentiment Impact: Positive news headlines from NAMS' upcoming presentations and investor conferences have contributed to the stock's recent price action.

Technical Analysis

Trend Direction: Short-term: BEARISH (MACD bearish crossover, Stochastic oversold) Medium-term: BULLISH (SMA 50 above SMA 20) Long-term: NEUTRAL (no clear trend)

Support/Resistance Levels:

  • Lower band: $25.42
  • Middle band: $27.16
  • Upper band: $28.89

Momentum Signals: RSI interpretation: Neutral (31.86), not oversold or overbought MACD signal: Bearish (crossover below signal line) Bollinger Bands position: Oversold, with potential for mean reversion

Volume Analysis: Volume rate of change is negative (-75.81%), suggesting institutional selling.

News & Sentiment Analysis

Recent Headlines Summary: NAMS has announced upcoming presentations and investor conferences, which have been well-received by the market.

Sentiment Assessment: Positive (aggregate sentiment from recent news headlines)

Catalyst Identification: Upcoming investor conferences and presentations in June

Market Narrative: The market narrative is focused on NAMS' potential for future growth, with investors awaiting further catalysts.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to the broader market (beta 1.05)

Volatility Regime: Above average volatility - stock moves with market amplification

Options Market Signals: Implied volatility premium is high (234.4%), indicating a higher probability of larger price movements.

Downside Protection: Support levels are present at $25.42 and $27.16, but the options market suggests a higher risk of a downside move in the near term.

Market Context & Positioning

Sector Performance: NAMS is outperforming its sector peers in terms of revenue growth (49% YoY).

Institutional Activity: Institutional interest is mixed, with some investors selling and others buying.

Correlation Analysis: The stock's correlation with the market is moderate (0.24), indicating a mix of independent and correlated movements.

Relative Valuation: NAMS is positioned within its trading range, with potential for mean reversion or breakout.

Key Levels & Action Items

Critical Price Levels:

  • Support level 1: $25.42
  • Resistance level 1: $28.89
  • Critical price level: $27.16 (SMA 50)

Breakout/Breakdown Levels: No clear levels, but the options market suggests a higher risk of a downside move in the near term.

Time-Sensitive Catalysts: Earnings reports and investor conferences in June

Risk Management: Stop-loss levels can be set at $24.60 (2% below current price) or $26.80 (4% above current price). Position sizing should consider the stock's high volatility and risk relative to the broader market.

This comprehensive analysis provides a detailed framework for understanding NAMS' technical, fundamental, and market-related factors. By acknowledging both bullish and bearish signals, investors can make more informed decisions regarding this high-risk, high-reward stock.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
19.59%
Avg Actual Move
2.44%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-06 After-Close 35.12% 0.18% 0.01x Within
2025-02-26 After-Close 15.35% 5.02% 0.33x Within
2025-05-08 After-Close 19.21% 3.76% 0.20x Within
2025-08-06 After-Close 19.79% 2.79% 0.14x Within
2025-11-05 After-Close 21.90% 2.95% 0.13x Within
2026-02-18 Pre-Market 6.87% 1.90% 0.28x Within
2026-08-05 Pre-Market 18.87% 0.47% 0.02x Within
Options Activity
IV Rank (30D)
44.84
IV Rank (7D)
44.84
Avg IV
100.1%
Straddle (30D)
$3.00
Straddle (7D)
$3.00
P/C Volume
0.02
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.12
Correlation (SPY)
26.2%
R²
0.07
Ann. Volatility
55.8%
SPY Volatility
13.0%

Above average volatility - stock moves with market amplification

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 120,627,683 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

198 filers123,247,406 shares$3.97B value102.17% of float
# Filer Shares Value % of Total % of Float Period
1 Frazier Life Sciences Management, L.P. 18,088,902 $613.03M 15.42% 15.00% 2026-06-30
2 Capital World Investors 12,230,557 $414.49M 10.43% 10.14% 2026-06-30
3 FMR LLC Custodian 10,339,663 $350.41M 8.82% 8.57% 2026-06-30
4 RA CAPITAL MANAGEMENT, L.P. 9,550,191 $323.66M 8.14% 7.92% 2026-06-30
5 FCPM III SERVICES B.V. 8,490,353 $287.74M 7.24% 7.04% 2026-06-30
6 DEERFIELD MANAGEMENT COMPANY, L.P. 4,264,789 $144.53M 3.64% 3.54% 2026-06-30
7 VIKING GLOBAL INVESTORS LP 4,203,567 $142.46M 3.58% 3.48% 2026-06-30
8 Bain Capital Life Sciences Investors, LLC 3,806,566 $129.00M 3.25% 3.16% 2026-06-30
9 MAVERICK CAPITAL LTD 3,267,802 $110.75M 2.79% 2.71% 2026-06-30
10 Jupiter Topco LLC 2,535,682 $86.01M 2.16% 2.10% 2026-06-30
11 Medicxi Ventures Management (Jersey) Ltd 2,208,639 $74.85M 1.88% 1.83% 2026-06-30
12 JANUS HENDERSON GROUP PLC 2,258,984 $72.25M 1.82% 1.87% 2026-03-31
13 JENNISON ASSOCIATES LLC 2,102,286 $71.25M 1.79% 1.74% 2026-06-30
14 Orbis Allan Gray Ltd 1,747,627 $59.23M 1.49% 1.45% 2026-06-30
15 Polar Capital Holdings Plc 1,724,518 $58.44M 1.47% 1.43% 2026-06-30
16 Capital International Investors 1,723,495 $58.41M 1.47% 1.43% 2026-06-30
17 GOLDMAN SACHS GROUP INC Custodian 1,544,911 $52.36M 1.32% 1.28% 2026-06-30
18 WESTFIELD CAPITAL MANAGEMENT CO LP 1,536,472 $52.07M 1.31% 1.27% 2026-06-30
19 Castle Hook Partners LP 1,371,005 $46.46M 1.17% 1.14% 2026-06-30
20 ALLIANCEBERNSTEIN L.P. 1,259,940 $40.33M 1.01% 1.04% 2026-06-30
21 JPMORGAN CHASE & CO Custodian 1,132,955 $38.37M 0.97% 0.94% 2026-06-30
22 Aberdeen Group plc 1,102,785 $37.37M 0.94% 0.91% 2026-06-30
23 BlackRock, Inc. Custodian 1,063,750 $36.05M 0.91% 0.88% 2026-06-30
24 FRANKLIN RESOURCES INC Custodian 993,917 $33.68M 0.85% 0.82% 2026-06-30
25 TimesSquare Capital Management, LLC 796,162 $26.98M 0.68% 0.66% 2026-06-30
8 filers$10.38M notional
# Filer Notional Value % of Total Period
1 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $5.02M 48.32% 2026-06-30
2 CITADEL ADVISORS LLC Custodian $1.30M 12.54% 2026-06-30
3 LMR Partners LLP $1.16M 11.13% 2026-06-30
4 Tidal Investments LLC $671.02K 6.46% 2026-06-30
5 Caption Management, LLC $633.74K 6.11% 2026-06-30
6 Point72 Asset Management, L.P. $620.19K 5.97% 2026-06-30
7 GOLDMAN SACHS GROUP INC Custodian $576.13K 5.55% 2026-06-30
8 JANE STREET GROUP, LLC Custodian $406.68K 3.92% 2026-06-30
8 filers$71.92M notional
# Filer Notional Value % of Total Period
1 Jefferies Financial Group Inc. $20.33M 28.27% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $19.27M 26.79% 2026-06-30
3 PERCEPTIVE ADVISORS LLC $16.95M 23.56% 2026-06-30
4 LMR Partners LLP $7.27M 10.11% 2026-06-30
5 BOOTHBAY FUND MANAGEMENT, LLC $4.11M 5.71% 2026-06-30
6 Caption Management, LLC $3.12M 4.34% 2026-06-30
7 Point72 Asset Management, L.P. $620.19K 0.86% 2026-06-30
8 JANE STREET GROUP, LLC Custodian $247.40K 0.34% 2026-06-30
Insider Activity
Latest: 2026-09-15
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-15 Michael H. Davidson Chief Executive Officer Buy (P) +10,000 $22.65 $226.5K EDGAR
2026-09-09 John W Smither Director Sell (S) −1,600 $25.32 -$40.5K EDGAR
2026-09-03 Robert William Gunning Vice President, Controller Award (A) +3,200 — EDGAR
2026-08-25 Johannes Jacob Pieter Kastelein Chief Scientific Officer Mixed — $26.91 -$3.36M EDGAR
2026-07-22 Louise Frederika Kooij Chief Accounting Officer Mixed — $20.84 -$1.99M EDGAR
2026-06-24 Louise Frederika Kooij Chief Accounting Officer Mixed — $20.74 -$757.2K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
5 insiders · @ $22.57
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Michael H. Davidson Chief Executive Officer 1,078,638 $24.34M $226.5K 1 2026-09-15
2 Johannes Jacob Pieter Kastelein Chief Scientific Officer 122,802 $2.77M -$3.36M 1 2026-08-25
3 Louise Frederika Kooij Chief Accounting Officer 24,353 $549.6K -$4.39M 2 2026-07-22
4 John W Smither Director 8,760 $197.7K -$40.5K 1 2026-09-09
5 Robert William Gunning Vice President, Controller 3,200 $72.2K $0 1 2026-09-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-08-25
Last 30d: 2 filings · $10.5M notice value  ·  Last 90d: 2 filings · $10.5M notice value · 1 unique filer · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Kastelein Johannes Jacob Pieter (2, $10.5M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-25 144/A Kastelein Johannes Jacob Pieter Affiliate 250,000 $6.97M 2026-08-25 J.P. Morgan Securities LLC 10b5-1 EDGAR
2026-08-24 Kastelein Johannes Jacob Pieter Affiliate 125,000 $3.48M 2026-08-24 J.P. Morgan Securities LLC 10b5-1 EDGAR
2026-05-26 Louise Kooij Officer 210,000 $7.44M 2026-05-26 J.P. Morgan Securities LLC 10b5-1 EDGAR
2026-03-11 Louis G. Lange Affiliate 44,619 $1.40M 2026-03-11 J.P. Morgan Securities LLC — EDGAR
2026-03-06 Louis G. Lange Affiliate 28,186 $878.8K 2026-03-06 J.P. Morgan Securities LLC 10b5-1 EDGAR
2026-03-05 Kastelein Johannes Jacob Pieter Affiliate 300,000 $9.35M 2026-03-02 J.P. Morgan Securities LLC 10b5-1 EDGAR
2026-03-02 Michael H. Davidson Affiliate 443,707 $15.73M 2026-03-02 J.P. Morgan Securities LLC — EDGAR
2026-02-24 Michael H. Davidson Affiliate 750,000 $27.13M 2026-02-24 J.P. Morgan Securities LLC 10b5-1 EDGAR
2026-02-20 Kastelein Johannes Jacob Pieter Officer, Director 45,481 $1.58M 2026-02-20 ABN AMRO — EDGAR
2026-01-20 Mayur Somaiya Affiliate 200,000 $6.33M 2026-01-20 J.P. Morgan Securities LLC 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio4.3
P/S Ratio380.7
EV/EBITDA-9.4
TTM Revenue$0.0B
TTM Net Income$-0.2B
TTM EPS$-1.91
ROE-41.1%